Annual report pursuant to Section 13 and 15(d)

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details)

v3.19.1
Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Earnings Per Share [Abstract]    
Net loss - as reported, before noncontrolling interest $ (18,172,822) $ (9,519,269)
Net loss attributable to noncontrolling interest 204,072
Net loss - as reported (17,968,750) (9,519,269)
Convertible Preferred Stock dividends Series B [1] (203,123)
Convertible Preferred Stock dividends Series A-1 [1] (25,148) (79,788)
Convertible Preferred Stock dividends Series A [1] (26,487) (112,570)
Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock (726,531)
Series A and Series A-1 Exchange Offer - March 15, 2018 - increase to additional paid-in capital - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock 199,241
Deemed dividend Series A-1 Convertible Preferred Stock (182,500)
Net loss attributable to PAVmed Inc. common stockholders $ (18,750,798) $ (10,398,134)
Weighted-average common shares outstanding basic and diluted [2] 22,276,347 13,495,951
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc [3] $ (0.81) $ (0.71)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders [3] $ (0.84) $ (0.77)
[1] The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: for the current year period - with respect to the Series B Convertible Preferred Stock, from March 16, 2018 to December 31, 2018, and with respect to each of the Series A-1 and Series A Convertible Preferred Stock, from January 1, 2018 to March 15, 2018; and, for the prior year period - with respect to the Series A Convertible Preferred Stock, from each of the respective Series A Preferred Stock Units private placement close dates from January 26, 2017, January 31, 2017, and March 8, 2018 to December 31, 2017; and, with respect to the Series A-1 Convertible Preferred Stock, from the Series A-1 Preferred Stock Units private placement close date from August 4, 2017 to December 31, 2017. See Note 13, Preferred Stock, for a further discussion of the dividends for each of the respective series of convertible preferred stock.
[2] Basic weighted-average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
[3] The Series B Convertible Preferred Stock has the right to receive common stock dividends, and prior to the March 15, 2018 Exchange Date of the Series A and Series A Exchange Offer, holders of the Series A Warrants and the Series A-1 Warrants previously had the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock and the Series A Warrants and Series A-1 Warrants would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company's net loss per share calculation for the periods indicated.